A Phase 3 interventional study of olanzapine and haloperidol in Bipolar Disorder, sponsored by Eli Lilly and Company. Completed at 16 sites in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-12-28.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.
Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 6th largest by enrollment, is one of 4 that started in 2005, is one of 7 in phase 3, and was the 6th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 20 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 224 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 120 across the 28 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Bipolar Disorder by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 20 studies in Bipolar Disorder by Eli Lilly and Company, this one is the 7th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 3, and was the 6th registered.
Eli Lilly and Company’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing olanzapine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 20 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
olanzapine: 5 to 20 mg per day for 6 weeks
Drug: olanzapine
haloperidol: 2.5 to 10 mg per day for 6 weeks
Drug: haloperidol
placebo for 3 weeks, then olanzapine 5 to 20 mg per day for 3 weeks
Drug: placebo
5-20 mg, oral, once daily (evening), for 6 weeks
Also known as: LY170053, Zyprexa
2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
placebo, oral tablets, twice daily (morning and evening), for 3 weeks
Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline, 3 weeks
Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS)
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
Time frame: Baseline, 6 weeks
Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol)
Remission of bipolar disorder was defined as completing the 6-week period with meeting the criteria for Young Mania Rating Scale (YMRS) total score of 12 or less and 17-Item Hamilton Depression Rating Scale (HAMD-17) total scores of 7 or less at Week 6. YMRS is an 11-item scale measuring severity of manic episodes; total score ranges = 0 (normal) to 60 (severe). The 17-item HAMD measures depression severity; total score ranges = 0 (normal) to 52 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.
Time frame: 6 weeks
Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness
A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of overall mood symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline, 6 weeks
Change From Baseline to 3 Week and 6 Week Endpoints in Clinical Global Impression - Bipolar Version (CGI-BP) Mania Subscale
A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of manic symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
Time frame: Baseline, 3 weeks, 6 weeks
Response Rate of Manic Symptoms at 3 Weeks and 6 Weeks
Participants who had 50 percent or more decrease from the baseline in YMRS total scores were defined as a responder. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. Response Rate (percent) = number of patients meeting response criterion for manic symptom divided by number of patients in treatment arm, multiplied by 100.
Time frame: Baseline, 3 weeks, 6 weeks
Remission Rate of Manic Symptoms at 3 Weeks and 6 Weeks
Participants who had a YMRS total score of 12 or less were considered to be in remission of manic symptoms. YMRS is an 11-item scale that measures severity of manic episodes; total score ranges from 0 (normal) to 60 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.
Time frame: 3 weeks, 6 weeks
Percentage of Participants Who Switched to Symptomatic Depression
Switch to symptomatic depression was defined as HAMD-17 total score ≥13 at any time in the participants with HAMD-17 total scores ≤7 at baseline. The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
Time frame: 3 weeks, 6 weeks
Change From Baseline to 3 Week and 6 Week Endpoints in the Positive Subscore of Positive and Negative Syndrome Scale (PANSS)
Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For this study, the score was converted to 0 to 6 for each item range; hence, the total positive subscale score ranges from 0 to 42.
Time frame: Baseline, 3 weeks, 6 weeks
Percentage of Participants Who Switched to Syndromic Depression
Switch to syndromic depression was operationally defined by meeting both of the following criteria: At baseline, the symptoms did not meet the criteria for a mixed episode based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). The critiera were met for a Major Depressive Episode (MDE), at any point after randomization, based on DSM-IV-TR. Rather than the 2-week period required for an MDE in the DSM-IV-TR, the patient had to meet the criteria of an MDE for at least 7 consecutive days (during Weeks 1 through 6).
Time frame: 3 weeks, 6 weeks
Maximum Change From Baseline During 6-Week Period in Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Total Score
Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe).
Time frame: Baseline to 6 weeks
| Milestone | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Started | 105 | 20 | 99 |
| Received at least one dose of study drug | 104 | 20 | 97 |
| Completed | 72 | 8 | 52 |
| Not completed | 33 | 12 | 47 |
| Withdrew: Adverse event | 9 | 5 | 7 |
| Withdrew: Lack of efficacy | 15 | 1 | 28 |
| Withdrew: Entry criteria not met | 2 | 0 | 2 |
| Withdrew: Protocol violation | 4 | 2 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 4 |
| Withdrew: Reason not specified | 2 | 0 | 5 |
| Milestone | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Started | 72 | 8 | 52 |
| Completed | 59 | 7 | 42 |
| Not completed | 13 | 1 | 10 |
| Withdrew: Adverse event | 1 | 0 | 3 |
| Withdrew: Protocol violation | 1 | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 | 3 |
| Withdrew: Sponsor decision | 1 | 0 | 0 |
| Withdrew: Reason not specified | 9 | 0 | 2 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Change From Baseline to 3 Week Endpoint in Young Mania Rating Scale (YMRS) Total Score | -12.6 ± 10.0 | -14.3 ± 11.4 | -6.8 ± 14.0 |
The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.
| units on a scale | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Change From Baseline to 6 Week Endpoint in Young Mania Rating Scale (YMRS) | -16.0 ± 11.4 | -14.7 ± 13.1 | -10.1 ± 15.8 |
Remission of bipolar disorder was defined as completing the 6-week period with meeting the criteria for Young Mania Rating Scale (YMRS) total score of 12 or less and 17-Item Hamilton Depression Rating Scale (HAMD-17) total scores of 7 or less at Week 6. YMRS is an 11-item scale measuring severity of manic episodes; total score ranges = 0 (normal) to 60 (severe). The 17-item HAMD measures depression severity; total score ranges = 0 (normal) to 52 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.
| percentage of participants | Olanzapine | Haloperidol |
|---|---|---|
| Remission Rate of Bipolar Disorder (Olanzapine Versus Haloperidol) | 44.2 | 20.0 |
A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of overall mood symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Change From Baseline to 6 Week Endpoint in Clinical Global Impressions - Bipolar Version (CGI-BP), Overall Severity of Illness | -1.6 ± 1.5 | -1.3 ± 1.8 | -0.9 ± 1.7 |
A global rating scale for severity of patients adapted to bipolar disorder. Measures severity of the patient's overall severity of manic symptoms on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
| units on a scale | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| 3-Week Change | -1.2 ± 1.2 | -1.7 ± 1.7 | -0.6 ± 1.5 |
| 6-Week Change | -1.7 ± 1.5 | -1.9 ± 1.9 | -1.0 ± 1.7 |
Participants who had 50 percent or more decrease from the baseline in YMRS total scores were defined as a responder. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. Response Rate (percent) = number of patients meeting response criterion for manic symptom divided by number of patients in treatment arm, multiplied by 100.
| percentage of participants | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| 3 Week Response Rate | 51.0 | 65.0 | 44.3 |
| 6 Week Response Rate | 67.3 | 65.0 | 55.7 |
Participants who had a YMRS total score of 12 or less were considered to be in remission of manic symptoms. YMRS is an 11-item scale that measures severity of manic episodes; total score ranges from 0 (normal) to 60 (severe). Remission Rate (percent) = number of patients meeting remission criteria divided by number of patients in treatment arm, multiplied by 100.
| percentage of participants | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| 3-Week Remission Rate | 47.1 | 65.0 | 41.2 |
| 6-Week Remission Rate | 63.5 | 60.0 | 52.6 |
Switch to symptomatic depression was defined as HAMD-17 total score ≥13 at any time in the participants with HAMD-17 total scores ≤7 at baseline. The 17-item HAMD measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).
| percentage of participants | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| 3-Week Symptomatic Depression Rate | 2.4 | 16.7 | 1.3 |
| 6-Week Symptomatic Depression Rate | 2.4 | 16.7 | 2.7 |
Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale (ex. delusions, conceptual disorganization, and hallucinatory behavior). Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For this study, the score was converted to 0 to 6 for each item range; hence, the total positive subscale score ranges from 0 to 42.
| units on a scale | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| 3-Week Change | -1.8 ± 4.1 | -1.8 ± 4.3 | -0.0 ± 5.3 |
| 6-Week Change | -2.2 ± 4.4 | -1.6 ± 4.3 | -0.3 ± 5.7 |
Switch to syndromic depression was operationally defined by meeting both of the following criteria: At baseline, the symptoms did not meet the criteria for a mixed episode based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR). The critiera were met for a Major Depressive Episode (MDE), at any point after randomization, based on DSM-IV-TR. Rather than the 2-week period required for an MDE in the DSM-IV-TR, the patient had to meet the criteria of an MDE for at least 7 consecutive days (during Weeks 1 through 6).
| percentage of participants | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| 3-Week Syndromic Depression Rate | 0.0 | 5.3 | 0.0 |
| 6-Week Syndromic Depression Rate | 1.1 | 5.3 | 0.0 |
Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment. Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe). The total score is the sum of the 8 item scores, for a total range of 0 (normal) to 32 (severe).
| units on a scale | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Baseline | 0.20 ± 0.66 | 0.50 ± 1.19 | 0.30 ± 0.91 |
| Maximum Change from Baseline | 0.70 ± 1.51 | 2.70 ± 2.89 | 0.09 ± 1.09 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Olanzapine | — | 1/105 (1%) | 78/105 (74.3%) |
| Haloperidol | — | 0/20 (0%) | 14/20 (70%) |
| Placebo | — | 3/96 (3.1%) | 64/96 (66.7%) |
| Event | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| Status epilepticusNervous system disorders | 0/105 | 0/20 | 1/96 |
| Bipolar I disorderPsychiatric disorders | 1/105 | 0/20 | 1/96 |
| ManiaPsychiatric disorders | 0/105 | 0/20 | 1/96 |
| Event | Olanzapine | Haloperidol | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 25/105 | 3/20 | 15/96 |
| ThirstGeneral disorders | 16/105 | 1/20 | 2/96 |
| AkathisiaNervous system disorders | 3/105 | 3/20 | 0/96 |
| DystoniaNervous system disorders | 0/105 | 3/20 | 1/96 |
| ConstipationGastrointestinal disorders | 10/105 | 2/20 | 3/96 |
| MalaiseGeneral disorders | 6/105 | 2/20 | 4/96 |
| NasopharyngitisInfections and infestations | 9/105 | 2/20 | 9/96 |
| TremorNervous system disorders | 3/105 | 2/20 | 1/96 |
| Weight increasedInvestigations | 10/105 | 1/20 | 4/96 |
| Increased appetiteMetabolism and nutrition disorders | 7/105 | 1/20 | 4/96 |
| Age Continuous(years) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Mean | 43.1 ± 12.0 | 49.3 ± 11.9 | 42.5 ± 10.9 | 43.4 ± 11.6 |
| Sex: Female, Male(Participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Female | 55 | 9 | 57 | 121 |
| Male | 49 | 11 | 40 | 100 |
| Race/Ethnicity, Customized(participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Japanese | 104 | 20 | 97 | 221 |
| Region of Enrollment(participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Japan | 104 | 20 | 97 | 221 |
| Current Illness Episode: Manic versus Mixed(participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Manic | 95 | 19 | 89 | 203 |
| Mixed | 9 | 1 | 8 | 18 |
| Current Illness Episode: Psychotic versus Nonpsychotic(participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Psychotic | 17 | 4 | 19 | 40 |
| Nonpsychotic | 87 | 16 | 78 | 181 |
| Hospitalization Status(participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| In-Patients | 41 | 10 | 38 | 89 |
| Out-Patients | 63 | 10 | 59 | 132 |
| Psychosis(participants) | Olanzapine | Haloperidol | Placebo | Total |
|---|---|---|---|---|
| Mood-Congruent | 16 | 4 | 19 | 39 |
| Mood-Incongruent | 1 | 0 | 0 | 1 |
8 further baseline measures are reported on the registry.
The record gives a start of Jul 2005, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine